EUVIMEDEUVIMED entdecken
Crossref

Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Bianca Bergamini, Julien Seneschal, Kristin J Meyers, Frederick Durand, Ewa Haladyj, Gerard Espinosa iD, Jacob P Thyssen

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Bianca Bergamini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Azetidines, Pregnancy Outcome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Information is needed to manage pregnancies with inadvertent exposure to baricitinib. A total of 117 pregnancies with exposure to baricitinib were identified among patients treated with baricitinib for rheumatoid arthritis, atopic dermatitis, or alopecia areata during clinical trials or in the postmarketing setting, and retrieved from the Eli Lilly global safety database. The clinical outcomes of the pregnancies with reported exposure to baricitinib appear to be comparable to those previously reported with other targeted therapies for immune-mediated diseases or in the general population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesPregnancy OutcomeFemaleHumansPregnancyProduct Surveillance, PostmarketingPurinesClinical Trials as TopicPyrazolesSulfonamides

Substanzen

AzetidinesPurinesbaricitinibPyrazolesSulfonamides

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Department of Dermatology, National Reference Center for Rare Skin Disorders, CNRS, UMR5164, ImmunoConCept, University of Bordeaux, Bordeaux, France.
  • Department of Autoimmune Diseases, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia,Spain.
  • Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Gerard Espinosa

Förderung

  • Eli Lilly and Company

Zitieren

APA

Bergamini, B., Seneschal, J., Meyers, K. J., Durand, F., Haladyj, E., Espinosa, G., & Thyssen, J. P. (2023). Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad279

Vancouver

Bergamini B, Seneschal J, Meyers KJ, Durand F, Haladyj E, Espinosa G, et al. Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad279

BibTeX
@article{Bergamini2023,
  author = {Bergamini, Bianca and Seneschal, Julien and Meyers, Kristin J and Durand, Frederick and Haladyj, Ewa and Espinosa, Gerard and Thyssen, Jacob P},
  title = {Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad279}
}
Kostenlos starten →